PT-141 | 10mg | Melanocortin Receptor Agonist

For In Vitro Research Use Only — Not for Human or Veterinary Use

Description

PT-141 (Bremelanotide) is a synthetic peptide analog of α-MSH (alpha-Melanocyte-Stimulating Hormone) that acts as a melanocortin receptor agonist, primarily targeting MC3R and MC4R pathways. It is widely studied for its influence on neurological and vascular signaling mechanisms related to arousal and energy balance.
In vitro research has explored PT-141’s role in modulating hypothalamic activity, stimulating melanocortin pathways, and affecting hemodynamic responses. This 10mg lyophilized formulation is produced under cGMP-grade conditions to support advanced biochemical and neurophysiological research.

Specifications

• Unit Size: 10mg

• Form: Lyophilized powder

• Storage: Store in a cool, dry environment (2°C–8°C). After reconstitution, refrigerate (2°C–8°C) and use within 10–14 days.

• Solubility: Soluble in sterile or bacteriostatic water

Research Applications

PT-141 is studied in controlled laboratory environments for potential roles in:

• Melanocortin receptor signaling (MC3R & MC4R)

• Neurovascular modulation

• CNS receptor mapping and signaling pathways

• Energy regulation and behavioral response studies

Intended Use

This compound is intended strictly for in vitro laboratory research by qualified professionals. It is not approved for human or animal use, nor for use in food, drugs, cosmetics, or diagnostics.

⚠️ Legal Disclaimer

All products from Pacific Edge Labs are intended solely for research and educational purposes. These materials have not been evaluated by the FDA and are not designed to diagnose, treat, cure, or prevent any disease. Access is restricted to certified research institutions and authorized scientific professionals operating under lawful research standards.

Terms of Sale

By purchasing from Pacific Edge Labs, the buyer affirms they are a qualified researcher or institution capable of safe handling, storage, and regulatory compliance. All sales are final.